Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GFB-887
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Karuna Therapeutics
Deal Size : $535.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Karuna will obtain exclusive global license to develop, manufacture, and commercialize multiple TRPC4/5 candidates, including lead clinical-stage candidate GFB-887 for the treatment of mood and anxiety disorders.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $15.0 million
February 02, 2023
Lead Product(s) : GFB-887
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Karuna Therapeutics
Deal Size : $535.0 million
Deal Type : Licensing Agreement
Lead Product(s) : GFB-887
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recent preliminary data from Phase 2 study of GFB-887 in focal segmental glomerular disease (FSGS) further validate feasibility and value of using transplanted human organoids in preclinical PD studies.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2022
Lead Product(s) : GFB-887
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GFB-024
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GFB-024 has the potential to provide disease-modifying effects in the kidney while treating the underlying metabolic dysfunction in obese patients without the CNS side-effects seen by prior small molecule CB1 antagonists.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 31, 2022
Lead Product(s) : GFB-024
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GFB-887
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Treatment with GFB-887 led to a statistically significant, clinically meaningful 32% placebo-adjusted mean reduction in urine protein creatine ratio (UPCR), with nine out of ten evaluable patients experiencing a reduction in UPCR.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2022
Lead Product(s) : GFB-887
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GFB-887
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Primary objective of the TRACTION-2 trial is to evaluate the clinical activity of multiple doses of GFB-887 in approximately 78 patients treated for 12 weeks, as measured by percent change from baseline in urine protein to creatine ratio (UPCR) in patien...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 11, 2021
Lead Product(s) : GFB-887
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GFB-887
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2021
Lead Product(s) : GFB-887
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GFB-024
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Goldfinch Bio observed that treatment with GFB-024 resulted in inhibition of CB1 receptor signaling, protecting against both podocyte and tubular cell injury, with negligible exposure in the brain and no central nervous system physiological effect.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 13, 2021
Lead Product(s) : GFB-024
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GFB-024
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 10, 2021
Lead Product(s) : GFB-024
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GFB-887
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Goldfinch is developing GFB-887, a first-in-class, highly potent and selective inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5), as a precision medicine for patients with kidney diseases characterized by overactivation of the TRPC5-R...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2020
Lead Product(s) : GFB-887
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GFB-887
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TRACTION-2 is a multicenter, double-blind, randomized, placebo controlled Phase 2 trial evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GFB-887 in approximately 125 patients with FSGS or DN.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2020
Lead Product(s) : GFB-887
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable